Mumbai: Health Impetus (HI), a disease management partner to global pharmaceutical and life sciences companies is all set to start its US operation in the next 2-3 months, eyeing a 50% growth in revenue over next two years, a top company official said.
“We are all set to ventur into US market in next 2-3 months. We see a buoyant market for its differentiated and unique health care services in the US. Currently, we are negotiating with pharma companies there to deliver on their ‘Disease management´ strategies with their product line,” Health Impetus chief executive officer, Pankaj Sindhu said in a statement here.
Initially, the company will open up its two offices in US and gradually expand its reach, he said adding, HI is now evaluating various options to increase its reach in that country.
The company has already approached various pharma companies in US to deliver on their ‘Disease Management´ strategies around their key product line, Sindhu said.
“Pharma companies do realise their additional responsibility of contributing to the positive treatment outcomes in patient’s lives in a highly compliant and ethical manner apart from their core manufacturing and marketing responsibilities. This gives a tremendous scope for HI to secure a high revenue growth from the US market, he said.
Sindhu said, the company is planning to work with top 20 global pharmaceutical companies in coming months.
Currently, in India, HI provides a differentiated positive treatment outcome approach for patients with a complete focus on ‘Patient Management´.
Health Impetus presently supports patients suffering from chronic diseases and ensures that the patient benefits from the regular intervention and engagement plan defined and customised as per the patients’ needs